<?xml version="1.0" encoding="UTF-8"?><marc:collection xmlns:marc="http://www.loc.gov/MARC21/slim">
  <marc:record>
    <marc:leader>00000nam##2200000za#4500</marc:leader>
    <marc:controlfield tag="001">9.646412</marc:controlfield>
    <marc:controlfield tag="003">CaOODSP</marc:controlfield>
    <marc:controlfield tag="005">20200328030041</marc:controlfield>
    <marc:controlfield tag="007">ta</marc:controlfield>
    <marc:controlfield tag="008">150407|1996||||xxc|||||     f|0| 0 eng|d</marc:controlfield>
    <marc:datafield tag="020" ind1=" " ind2=" ">
      <marc:subfield code="a">0-662-25269-1</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="040" ind1=" " ind2=" ">
      <marc:subfield code="a">CaOODSP</marc:subfield>
      <marc:subfield code="b">eng</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="043" ind1=" " ind2=" ">
      <marc:subfield code="a">n-cn---</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="086" ind1="1" ind2=" ">
      <marc:subfield code="a">H21-135/6-1996E</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="110" ind1="1" ind2=" ">
      <marc:subfield code="a">Canada. </marc:subfield>
      <marc:subfield code="b">Health Canada.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="245" ind1="1" ind2="0">
      <marc:subfield code="a">714-X: an information package / </marc:subfield>
      <marc:subfield code="c">Issued by the Canadian Breast Cancer Research Initiative. </marc:subfield>
    </marc:datafield>
    <marc:datafield tag="260" ind1=" " ind2=" ">
      <marc:subfield code="a">Toronto - Ontario : </marc:subfield>
      <marc:subfield code="b">Health Canada </marc:subfield>
      <marc:subfield code="c">1996.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="300" ind1=" " ind2=" ">
      <marc:subfield code="a">ix, 128p. : </marc:subfield>
      <marc:subfield code="c">28 cm.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="500" ind1=" " ind2=" ">
      <marc:subfield code="a">"714-X is an unconventional cancer therapy developed by Mr. Gaston Naessens, a French-born scientist and researcher, who has worked out of a privately financed laboratory in Quebec for more than 30 years."--Page 3. "One in a series of six Information Packages that attempt to collect, collate and review the available information concerning the safety and effectiveness of specific unconventional agents.... In each case the Information Package has a particular focus on the safety and effectiveness of the agent as a treatment for cancer as opposed to its potential role in prevention or its other health-related effects."--Preface.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="504" ind1=" " ind2=" ">
      <marc:subfield code="a">Bibliography.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="520" ind1="3" ind2=" ">
      <marc:subfield code="a">714-X is an unconventional cancer therapy developed by Mr. Gaston Naessens, a French-born scientist and researcher, who has worked out of a privately financed laboratory in Quebec for more than 30 years.--Page 3 One in a series of six Information Packages that attempt to collect, collate and review the available information concerning the safety and effectiveness of specific unconventional agents.... In each case the Information Package has a particular focus on the safety and effectiveness of the agent as a treatment for cancer as opposed to its potential role in prevention or its other health-related effects.--Preface</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="563" ind1=" " ind2=" ">
      <marc:subfield code="a">Softcover</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="590" ind1=" " ind2=" ">
      <marc:subfield code="a">97-11</marc:subfield>
      <marc:subfield code="b">1997-03-14</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="986" ind1=" " ind2=" ">
      <marc:subfield code="a">110-866</marc:subfield>
    </marc:datafield>
  </marc:record>
</marc:collection>
